Nothing Special   »   [go: up one dir, main page]

MX2013011721A - Metodos para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2. - Google Patents

Metodos para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.

Info

Publication number
MX2013011721A
MX2013011721A MX2013011721A MX2013011721A MX2013011721A MX 2013011721 A MX2013011721 A MX 2013011721A MX 2013011721 A MX2013011721 A MX 2013011721A MX 2013011721 A MX2013011721 A MX 2013011721A MX 2013011721 A MX2013011721 A MX 2013011721A
Authority
MX
Mexico
Prior art keywords
masp
complement activation
dependent complement
methods
dependent
Prior art date
Application number
MX2013011721A
Other languages
English (en)
Other versions
MX339002B (es
Inventor
Hans-Wilhelm Schwaeble
Gregory A Demopulos
Tom Dudler
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of MX2013011721A publication Critical patent/MX2013011721A/es
Publication of MX339002B publication Critical patent/MX339002B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)

Abstract

En un aspecto, la invención proporciona métodos para inhibir los efectos de la activación de complemento dependiente de MASP-2 en un sujeto vivo. Los métodos comprenden los pasos de administrar, a un sujeto en necesidad del mismo, una cantidad eficaz de un agente inhibidor de MASP-2 para inhibir la activación del complemento dependiente de MASP-2. En algunas modalidades, el agente inhibidor de MASP-2 inhibe la lesión celular asociada con la activación de la vía del complemento alternativa mediada por MASP-2, mientras deja al componente de la vía clásica (dependiente de C1q) intacta. En otro aspecto, la invención proporciona composiciones para inhibir los efectos de la activación de complemento dependiente de lectina, comprendiendo una cantidad terapéuticamente eficaz de un agente inhibidor de MASP-2 y un vehículo farmacéuticamente aceptable.
MX2013011721A 2011-04-08 2012-04-06 El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2. MX339002B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161473698P 2011-04-08 2011-04-08
PCT/US2012/032650 WO2012139081A2 (en) 2011-04-08 2012-04-06 Methods for treating conditions associated with masp-2 dependent complement activation

Publications (2)

Publication Number Publication Date
MX2013011721A true MX2013011721A (es) 2014-03-05
MX339002B MX339002B (es) 2016-05-06

Family

ID=46966283

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013011721A MX339002B (es) 2011-04-08 2012-04-06 El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.
MX2016006039A MX355648B (es) 2011-04-08 2012-04-06 El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016006039A MX355648B (es) 2011-04-08 2012-04-06 El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.

Country Status (18)

Country Link
US (5) US8951522B2 (es)
EP (3) EP3964233A1 (es)
JP (4) JP5937197B2 (es)
KR (6) KR101720562B1 (es)
CN (3) CN107638565B (es)
AU (1) AU2012239889B2 (es)
BR (1) BR112013025917A2 (es)
CA (4) CA2832187C (es)
CL (1) CL2013002874A1 (es)
DK (2) DK2694108T3 (es)
ES (2) ES2894342T3 (es)
HK (1) HK1250342A1 (es)
IL (3) IL228758B (es)
MX (2) MX339002B (es)
NZ (5) NZ709997A (es)
PL (1) PL3287142T3 (es)
RU (2) RU2662563C2 (es)
WO (1) WO2012139081A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
KR101720562B1 (ko) 2011-04-08 2017-03-30 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
EP2794656B1 (en) 2011-12-21 2019-02-27 Novartis AG Compositions comprising antibodies targeting factor p and c5
DK3366307T3 (da) * 2012-04-06 2021-11-01 Omeros Corp Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri
AU2013277309B2 (en) * 2012-06-18 2018-03-29 Omeros Corporation Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders
JP6538561B2 (ja) 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
AU2013337638B2 (en) 2012-11-02 2018-10-25 Bioverativ Usa Inc. Anti-complement C1s antibodies and uses thereof
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
CA2906096C (en) * 2013-03-15 2022-03-15 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
RS61351B1 (sr) 2013-10-17 2021-02-26 Omeros Corp Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
WO2015070041A1 (en) * 2013-11-08 2015-05-14 Icahn School Of Medicine At Mount Sinai Methods for monitoring kidney dysfunction
WO2015191951A2 (en) 2014-06-12 2015-12-17 Ra Pharmaceuticals, Inc. Modulation of complement activity
JP6640229B2 (ja) 2015-01-28 2020-02-05 ラ ファーマシューティカルズ インコーポレイテッドＲａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 補体活性の変調剤
ES2938359T3 (es) 2015-04-06 2023-04-10 Bioverativ Usa Inc Anticuerpos humanizados anti-C1s y métodos de uso de los mismos
US20170137537A1 (en) * 2015-11-09 2017-05-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
TWI745320B (zh) 2015-12-16 2021-11-11 美商Ｒａ製藥公司 補體活性之調節劑
HRP20211608T1 (hr) * 2015-12-23 2022-01-21 eleva GmbH Polipeptidi za inhibiranje aktivacije komplementa
SG10202001580SA (en) 2016-01-05 2020-04-29 Univ Leicester Methods for inhibiting fibrosis in a subject in need thereof
EP3436072A4 (en) 2016-03-31 2019-11-06 Omeros Corporation METHODS OF INHIBITING ANGIOGENESIS IN A SUBJECT THAT NEEDS
UY37376A (es) * 2016-08-26 2018-03-23 Amgen Inc Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
JOP20190068A1 (ar) * 2016-10-13 2019-04-01 Omeros Corp طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي
CN110087668A (zh) 2016-12-07 2019-08-02 Ra制药公司 补体活性的调节剂
JP6442703B2 (ja) * 2016-12-26 2018-12-26 日本ビーシージー製造株式会社 細菌細胞壁骨格成分を含有する水中油型エマルション製剤
CN110506116A (zh) * 2017-03-09 2019-11-26 协和麒麟株式会社 抑制masp2表达的核酸
CN116898870A (zh) * 2017-07-28 2023-10-20 雷莫内克斯生物制药有限公司 用于预防或治疗肝癌的药物组合物
AU2018377716A1 (en) 2017-12-01 2020-04-09 Suzhou Ribo Life Science Co., Ltd Nucleic acid, composition and conjugate containing same, and preparation method and use
JP7273417B2 (ja) 2017-12-01 2023-05-15 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
TW201938184A (zh) 2017-12-04 2019-10-01 美商Ｒａ製藥公司 補體活性之調節劑
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
JP7536655B2 (ja) * 2018-05-29 2024-08-20 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
RU2699040C1 (ru) * 2018-07-23 2019-09-03 Федеральное государственное бюджетное учреждение науки "Уральский научно-практический центр радиационной медицины Федерального медико-биологического агентства" (ФГБУН УНПЦ РМ ФМБА России) Способ экстренной профилактики и лечения острой лучевой болезни (варианты)
US11918600B2 (en) 2018-08-21 2024-03-05 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
EP3628735A1 (en) * 2018-09-25 2020-04-01 Centre National De La Recherche Scientifique Antisense rna targeting pmp22 for the treatment of charcot-marie-tooth 1a disease
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
MX2021005758A (es) * 2018-11-15 2021-09-21 Ionis Pharmaceuticals Inc Moduladores de la expresión de irf5.
WO2020132844A1 (zh) * 2018-12-25 2020-07-02 中国医学科学院基础医学研究所 炎性相关疾病防治的小rna药物及其组合
CA3131927A1 (en) 2019-03-08 2020-09-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
JP7530106B2 (ja) * 2019-03-14 2024-08-07 レナセラピューティクス株式会社 Ｉｈｈ発現を調節するための核酸複合体
CA3134614A1 (en) 2019-03-29 2020-10-08 Ra Pharmaceuticals, Inc. Complement modulators and related methods
MX2021013010A (es) 2019-04-24 2022-01-18 Ra Pharmaceuticals Inc Composiciones y metodos para modular la actividad del complemento.
CN113614230B (zh) * 2019-05-22 2024-04-09 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
CN111024947A (zh) * 2019-11-19 2020-04-17 江苏美克医学技术有限公司 白色念珠菌荧光免疫层析测定试剂盒及其制备方法
JP7227401B2 (ja) 2019-11-27 2023-02-21 京セラ株式会社 通信制御方法及びユーザ装置
CN115103709A (zh) 2019-12-04 2022-09-23 奥默罗斯公司 Masp-2抑制剂和使用方法
EP4069678A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
AU2020395306A1 (en) 2019-12-04 2022-06-30 Omeros Corporation MASP-2 inhibitors and methods of use
BR112022010890A2 (pt) 2019-12-04 2022-08-16 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado a serina protease-2 associada à lectina de ligação ao manan
WO2021168148A1 (en) * 2020-02-19 2021-08-26 Alnylam Pharmaceuticals, Inc. Mannan binding lectin serine peptidase 2 (masp2) irna compositions and methods of use thereof
KR102314642B1 (ko) * 2020-04-17 2021-10-20 재단법인 아산사회복지재단 파브리 병 진단용 바이오 마커 및 이의 용도
CN113674860B (zh) * 2020-05-15 2024-05-17 北京大学人民医院 一种难治性iTTP风险预测装置、系统及其应用
CA3182800A1 (en) 2020-06-14 2021-12-23 Vertex Pharmaceuticals Inc. Complement factor i-related compositions and methods
WO2022228364A1 (zh) * 2021-04-25 2022-11-03 江苏恒瑞医药股份有限公司 抗masp2抗体、其抗原结合片段及医药用途
CR20240271A (es) 2021-12-10 2024-08-12 Omeros Corp Anticuerpos que se unen al dominio serina proteasa de masp-2
WO2024026258A2 (en) * 2022-07-25 2024-02-01 Amgen Inc. Rnai constructs and methods for inhibiting fam13a expression
WO2024118840A1 (en) 2022-11-30 2024-06-06 Omeros Corporation Fused pyrimidines as masp-2 inhibitors

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526909A (en) 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
DE3852539T3 (de) 1987-12-15 2005-08-04 Gene Shears Pty. Ltd. Ribozyme.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69030172T2 (de) 1990-01-26 1997-06-19 Immunomedics Inc Impfstoffe gegen Krebs und Infektionskrankheiten
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
JPH07238100A (ja) 1994-02-25 1995-09-12 Sumitomo Electric Ind Ltd ヒトのｍａｓｐに対するモノクローナル抗体
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6297024B1 (en) 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
US7273925B1 (en) 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
JP2002532079A (ja) 1998-12-15 2002-10-02 ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド 補体活性化に関連するレクチン補体経路を調節するための方法および産物
US6235494B1 (en) 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
RU2271825C2 (ru) 1999-07-21 2006-03-20 Омерос Корпорейшн Растворы и способы ингибирования боли, воспаления и разрушения хряща
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US20030186419A1 (en) 1999-12-02 2003-10-02 Jensenius Jens Christian Masp-3, a complement-fixing enzyme, and uses for it
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
DK1303591T3 (da) 2000-07-13 2009-11-02 Helion Biotech Aps MASP-2, et komplementfikserende enzym, og anvendelser af det
WO2003009803A2 (en) 2001-07-26 2003-02-06 Alexion Pharmaceuticals Inc. Method of improving cognitive function
JP2005519917A (ja) 2002-02-01 2005-07-07 オメロス コーポレイション 軟骨分解の全身阻害のための組成物および方法
US20050221382A1 (en) 2002-03-18 2005-10-06 Rother Russell P Stratification of patient populations having or suspected of having rheumatoid arthritis
CN100519643C (zh) 2002-07-19 2009-07-29 奥默罗斯公司 可生物降解的三嵌段共聚物,它们的合成方法和从它制得的水凝胶和生物材料
PT1534313E (pt) 2002-07-30 2013-01-25 Omeros Corp Soluções e método de irrigação oftalmológica
ITRM20020511A1 (it) * 2002-10-09 2004-04-10 Santa Anna Acuto Uso dell'insulator sns di riccio di mare per la terapia genica di malattie delle cellule eritroidi.
WO2004050907A2 (en) 2002-12-03 2004-06-17 Aarhus Universitet Method for determing predisposition to manifestation of immune system related diseases
MXPA05008570A (es) 2003-02-21 2005-11-04 Tanox Inc Metodos para la prevencion y tratamiento de danos tisulares asociados con una lesion por isquemia-reperfusion.
JP4680770B2 (ja) * 2003-03-17 2011-05-11 一般財団法人化学及血清療法研究所 フォンビルブランド因子特異的切断酵素に対する抗体の認識領域からなる構成物
US9096676B2 (en) 2003-05-12 2015-08-04 Helion Biotech Aps Antibodies to MASP-2
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
WO2005123776A1 (en) 2004-06-10 2005-12-29 Omeros Corporation Methods for treating conditions associated with lectin-dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2382991A1 (en) 2004-06-10 2011-11-02 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
ES2382104T3 (es) 2005-06-17 2012-06-05 Baxter International Inc. Composiciones con actividad trombolítica que comprenden ADAMTS13
CA2640167A1 (en) 2006-01-27 2007-08-02 Rappaport Family Institute For Research In The Medical Sciences Methods and kits for determining blood coagulation
RU2477137C2 (ru) 2006-03-08 2013-03-10 АРКЕМИКС Эл Эл Си Связывающие комплемент аптамеры и средства против с5, пригодные для лечения глазных нарушений
EP2894165B1 (en) * 2008-11-10 2023-01-04 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
NZ597259A (en) * 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
AU2010272483B2 (en) 2009-07-17 2016-07-21 Omeros Corporation MASP isoforms as inhibitors of complement activation
CN102781471B (zh) 2009-10-16 2016-10-12 奥默罗斯公司 通过抑制masp-2依赖性补体活化治疗弥散性血管内凝血的方法
EP2496259B1 (en) * 2009-11-05 2017-02-22 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria
WO2011109338A1 (en) 2010-03-01 2011-09-09 Alexion Pharmaceuticals Inc. Methods and compositions for treating degos' disease
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
KR101720562B1 (ko) 2011-04-08 2017-03-30 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
US20150166676A1 (en) 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
MX361175B (es) 2011-05-04 2018-11-29 Omeros Corp Composiciones para inhibir la activación del complemento dependiente de la masp-2.
AU2013277309B2 (en) 2012-06-18 2018-03-29 Omeros Corporation Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders
RS61351B1 (sr) 2013-10-17 2021-02-26 Omeros Corp Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
US20170137537A1 (en) 2015-11-09 2017-05-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
WO2018070521A1 (ja) * 2016-10-14 2018-04-19 公立大学法人福島県立医科大学 補体の活性化経路を阻害する融合ポリペプチド

Also Published As

Publication number Publication date
US20220089781A1 (en) 2022-03-24
RU2018125514A (ru) 2019-03-12
KR102217658B1 (ko) 2021-02-22
DK3287142T3 (da) 2021-11-01
EP2694108A4 (en) 2014-10-01
KR20210021101A (ko) 2021-02-24
IL264172B (en) 2022-04-01
CN110075294A (zh) 2019-08-02
CA2977009A1 (en) 2012-10-11
RU2662563C2 (ru) 2018-07-26
CL2013002874A1 (es) 2014-03-07
JP2014512363A (ja) 2014-05-22
AU2012239889B2 (en) 2015-09-03
CA2977009C (en) 2020-05-05
JP2016185966A (ja) 2016-10-27
HK1250342A1 (zh) 2018-12-14
IL228758B (en) 2019-12-31
CN107638565B (zh) 2021-12-21
JP6239030B2 (ja) 2017-11-29
NZ617298A (en) 2015-08-28
ES2683307T3 (es) 2018-09-26
IL264172A (en) 2019-02-28
EP3287142B1 (en) 2021-08-04
US10202465B2 (en) 2019-02-12
US20120258095A1 (en) 2012-10-11
CA3076975C (en) 2024-06-18
IL228758A0 (en) 2013-12-31
CA3237802A1 (en) 2012-10-11
US20150239985A1 (en) 2015-08-27
JP6893539B2 (ja) 2021-06-23
JP2019214616A (ja) 2019-12-19
JP5937197B2 (ja) 2016-06-22
KR101720562B1 (ko) 2017-03-30
KR20220044616A (ko) 2022-04-08
US8951522B2 (en) 2015-02-10
MX339002B (es) 2016-05-06
AU2012239889A1 (en) 2013-03-14
KR20190142445A (ko) 2019-12-26
ES2894342T3 (es) 2022-02-14
PL3287142T3 (pl) 2021-12-27
NZ731596A (en) 2022-07-01
NZ717517A (en) 2017-07-28
JP6584476B2 (ja) 2019-10-02
CN107638565A (zh) 2018-01-30
RU2013149792A (ru) 2015-05-20
NZ746139A (en) 2023-11-24
NZ709997A (en) 2016-03-31
DK2694108T3 (en) 2018-08-20
CA2832187C (en) 2017-10-10
CN103781492A (zh) 2014-05-07
KR20140009472A (ko) 2014-01-22
CA2832187A1 (en) 2012-10-11
BR112013025917A2 (pt) 2016-12-20
EP2694108B1 (en) 2018-06-06
RU2018125514A3 (es) 2019-10-30
WO2012139081A2 (en) 2012-10-11
MX355648B (es) 2018-04-26
KR101870915B1 (ko) 2018-06-25
RU2743409C2 (ru) 2021-02-18
WO2012139081A3 (en) 2012-11-29
US20190292272A1 (en) 2019-09-26
US20170166658A1 (en) 2017-06-15
EP3287142A1 (en) 2018-02-28
KR20170034941A (ko) 2017-03-29
IL274206A (en) 2020-06-30
CA3076975A1 (en) 2012-10-11
EP2694108A2 (en) 2014-02-12
EP3964233A1 (en) 2022-03-09
JP2018024698A (ja) 2018-02-15
KR20180072851A (ko) 2018-06-29

Similar Documents

Publication Publication Date Title
MX2013011721A (es) Metodos para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.
MX2012004343A (es) Metodos para el tratamiento de la coagulacion intravascular diseminada mediante la inhibicion de la activacion del complemento dependiente de la masp-2.
MX366119B (es) Uso de un agente inhibidor de masp-2 para el tratamiento de condiciones renales mediadas por complemento dependiente de la masp-2.
MX2021008044A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
MX2022005200A (es) Composiciones y metodos para modular la expresion de angiotensinogeno.
WO2005123128A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
PH12016500649A1 (en) Combinations of histone deactylase inhibitors and immunomodulatory drugs
NZ742987A (en) Methods for treating conditions associated with masp-2 dependent complement activation
PH12020500276A1 (en) Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
MX357540B (es) Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
WO2013024282A3 (en) Inhibitor or down- regulator of the expression of one or both of tbk1 ikk-epsilon for use in the treatment of pi3kinase dependent cancer
WO2012078633A8 (en) Methods of inhibiting metastasis from cancer
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX2017011018A (es) Inhibicion de la actividad de olig2.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
WO2014186623A3 (en) Methods and compositions for the treatment of a chagas disease
UY34896A (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
MX2015013151A (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
MX2019013207A (es) Metodos y composiciones para tratar la endometriosis y sintomas asociados a la endometriosis.
MX2019001425A (es) Composiciones y el uso de las mismas para el tratamiento o la prevención de la rosácea.
TR201819348T4 (tr) Otizm Bozukluklarının Mentol, Linalool ve/veya İsilin İle Tedavisi ya da Önlenmesi

Legal Events

Date Code Title Description
FG Grant or registration